Saltar al contenido
Merck
  • Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Cancer cell (2018-08-15)
Marlies Vanden Bempt, Sofie Demeyer, Michaël Broux, Jolien De Bie, Simon Bornschein, Nicole Mentens, Roel Vandepoel, Ellen Geerdens, Enrico Radaelli, Beat C Bornhauser, Andreas E Kulozik, Jules P Meijerink, Jean-Pierre Bourquin, Charles E de Bock, Jan Cools
RESUMEN

The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in driving T-ALL development using a transgenic mouse model and human T-ALL cells. Using integrated ChIP-sequencing, ATAC-sequencing, and RNA-sequencing data, we demonstrate that TLX1 and STAT5, the downstream effector of NUP214-ABL1, co-bind poised enhancer regions, and cooperatively activate the expression of key proto-oncogenes such as MYC and BCL2. Inhibition of STAT5, downregulation of TLX1 or MYC, or interference with enhancer function through BET-inhibitor treatment leads to reduction of target gene expression and induction of leukemia cell death.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
IGEPAL® CA-630, for molecular biology
Sigma-Aldrich
Anti-β-actina monoclonal antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
Reactivo de transfección GeneJuice®, Non-lipid based chemical transfection reagent optimized for maximum transfection efficiency, ease-of-use, and minimal cytotoxicity on a wide variety of mammalian cells.
Sigma-Aldrich
Anticuerpo anti-trimetil-histona H3 (Lys27), Upstate®, from rabbit
Sigma-Aldrich
Sodium orthovanadate, 99.98% trace metals basis
Sigma-Aldrich
I-BET762, ≥98% (HPLC)